LivaNova PLC (NASDAQ:LIVN) Receives $69.17 Consensus PT from Analysts

Shares of LivaNova PLC (NASDAQ:LIVN) have been given a consensus rating of “Buy” by the seven analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $69.17.

Several equities analysts have recently issued reports on the stock. StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Robert W. Baird lifted their price target on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Mizuho dropped their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. Needham & Company LLC restated a “buy” rating and issued a $75.00 target price on shares of LivaNova in a report on Monday, November 25th. Finally, The Goldman Sachs Group started coverage on LivaNova in a research report on Friday, October 4th. They set a “buy” rating and a $65.00 target price on the stock.

Insider Activity

In other news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares of the company’s stock, valued at $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.27% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Nordea Investment Management AB boosted its stake in shares of LivaNova by 22.2% during the 4th quarter. Nordea Investment Management AB now owns 68,711 shares of the company’s stock valued at $3,188,000 after buying an additional 12,470 shares during the period. Driehaus Capital Management LLC raised its holdings in shares of LivaNova by 64.7% during the second quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock worth $29,824,000 after acquiring an additional 213,749 shares in the last quarter. Harbor Capital Advisors Inc. acquired a new stake in LivaNova during the fourth quarter valued at $1,954,000. Perceptive Advisors LLC grew its stake in LivaNova by 48.5% in the second quarter. Perceptive Advisors LLC now owns 444,000 shares of the company’s stock valued at $24,340,000 after purchasing an additional 145,000 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in LivaNova by 3.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 797,284 shares of the company’s stock worth $41,889,000 after purchasing an additional 25,277 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Trading Down 1.4 %

Shares of LIVN stock opened at $48.15 on Wednesday. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The stock has a 50-day simple moving average of $49.11 and a 200 day simple moving average of $49.99. LivaNova has a fifty-two week low of $43.15 and a fifty-two week high of $64.47. The stock has a market capitalization of $2.61 billion, a P/E ratio of 114.64 and a beta of 1.01.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.